SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-044066
Filing Date
2024-04-12
Accepted
2024-04-12 16:26:07
Documents
17
Period of Report
2024-04-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A kura-20240412.htm   iXBRL DEF 14A 1632712
2 GRAPHIC img1234521_0.jpg GRAPHIC 2071
3 GRAPHIC img1234521_1.jpg GRAPHIC 319429
4 GRAPHIC img1234521_2.jpg GRAPHIC 247939
5 GRAPHIC img1234521_3.jpg GRAPHIC 2573
6 GRAPHIC img1234521_4.jpg GRAPHIC 1390998
7 GRAPHIC img1234521_5.jpg GRAPHIC 170767
  Complete submission text file 0000950170-24-044066.txt   7281350

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20240412.xsd EX-101.SCH 69837
20 EXTRACTED XBRL INSTANCE DOCUMENT kura-20240412_htm.xml XML 144032
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37620 | Film No.: 24841822
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)